246 related articles for article (PubMed ID: 26895097)
21. The role of chemotherapy in the treatment of esophageal cancer.
Forastiere A
Clin Adv Hematol Oncol; 2005 Apr; 3(4):254-6. PubMed ID: 16166996
[No Abstract] [Full Text] [Related]
22. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
Karamouzis MV; Grandis JR; Argiris A
JAMA; 2007 Jul; 298(1):70-82. PubMed ID: 17609492
[TBL] [Abstract][Full Text] [Related]
23. Emerging drugs for esophageal cancer.
Homs MY; Voest EE; Siersema PD
Expert Opin Emerg Drugs; 2009 Jun; 14(2):329-39. PubMed ID: 19453287
[TBL] [Abstract][Full Text] [Related]
24. Clinical management of advanced gastric cancer: the role of new molecular drugs.
De Vita F; Di Martino N; Fabozzi A; Laterza MM; Ventriglia J; Savastano B; Petrillo A; Gambardella V; Sforza V; Marano L; Auricchio A; Galizia G; Ciardiello F; Orditura M
World J Gastroenterol; 2014 Oct; 20(40):14537-58. PubMed ID: 25356019
[TBL] [Abstract][Full Text] [Related]
25. HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy.
Ha SY; Lee J; Jang J; Hong JY; Do IG; Park SH; Park JO; Choi MG; Sohn TS; Bae JM; Kim S; Kim M; Kim S; Park CK; Kang WK; Kim KM
Int J Cancer; 2015 Apr; 136(7):1629-35. PubMed ID: 25157953
[TBL] [Abstract][Full Text] [Related]
26. Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies.
Cappetta A; Lonardi S; Pastorelli D; Bergamo F; Lombardi G; Zagonel V
Crit Rev Oncol Hematol; 2012 Jan; 81(1):38-48. PubMed ID: 21256046
[TBL] [Abstract][Full Text] [Related]
27. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
Jotte RM; Spigel DR
Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719
[TBL] [Abstract][Full Text] [Related]
28. Combined targeted therapies in non-small cell lung cancer: a winner strategy?
Cascone T; Gridelli C; Ciardiello F
Curr Opin Oncol; 2007 Mar; 19(2):98-102. PubMed ID: 17272980
[TBL] [Abstract][Full Text] [Related]
29. Novel targeted therapies for advanced esophageal cancer.
Lin CC; Papadopoulos KP
Dis Esophagus; 2007; 20(5):365-71. PubMed ID: 17760648
[TBL] [Abstract][Full Text] [Related]
30. Molecular signaling and the role of targeted therapies in bladder cancer.
Black PC
Minerva Urol Nefrol; 2012 Mar; 64(1):7-17. PubMed ID: 22402314
[TBL] [Abstract][Full Text] [Related]
31. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
Cortés J; Dieras V; Ro J; Barriere J; Bachelot T; Hurvitz S; Le Rhun E; Espié M; Kim SB; Schneeweiss A; Sohn JH; Nabholtz JM; Kellokumpu-Lehtinen PL; Taguchi J; Piacentini F; Ciruelos E; Bono P; Ould-Kaci M; Roux F; Joensuu H
Lancet Oncol; 2015 Dec; 16(16):1700-10. PubMed ID: 26596672
[TBL] [Abstract][Full Text] [Related]
32. Sunitinib malate for the treatment of renal cell carcinoma.
Wood L
Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
[TBL] [Abstract][Full Text] [Related]
33. Epidermal growth factor receptor: an important target in esophageal cancer.
Hong L; Han Y; Brain L
Expert Opin Ther Targets; 2013 Oct; 17(10):1179-85. PubMed ID: 23855932
[TBL] [Abstract][Full Text] [Related]
34. Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies.
Matsuoka T; Yashiro M
World J Gastroenterol; 2016 Jan; 22(2):776-89. PubMed ID: 26811624
[TBL] [Abstract][Full Text] [Related]
35. Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight.
Aprile G; Ongaro E; Del Re M; Lutrino SE; Bonotto M; Ferrari L; Rihawi K; Cardellino GG; Pella N; Danesi R; Fasola G
Crit Rev Oncol Hematol; 2015 Aug; 95(2):165-78. PubMed ID: 25800976
[TBL] [Abstract][Full Text] [Related]
36. Biomarkers of drugs targeting HER-family signalling in cancer.
Montemurro F; Scaltriti M
J Pathol; 2014 Jan; 232(2):219-29. PubMed ID: 24105684
[TBL] [Abstract][Full Text] [Related]
37. Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN).
Launay-Vacher V; Aapro M; De Castro G; Cohen E; Deray G; Dooley M; Humphreys B; Lichtman S; Rey J; Scotté F; Wildiers H; Sprangers B
Ann Oncol; 2015 Aug; 26(8):1677-84. PubMed ID: 25735315
[TBL] [Abstract][Full Text] [Related]
38. Epidermal growth factor receptor: pathway, therapies, and pipeline.
Goffin JR; Zbuk K
Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
[TBL] [Abstract][Full Text] [Related]
39. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
Pennell NA; Lynch TJ
Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
[TBL] [Abstract][Full Text] [Related]
40. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
Pietras K; Hanahan D
J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]